Finances - 2/31

Entry	Author	Date	Location
Will Biotech Ever Again Captivate the Public Imagination, Like Facebook or LinkedIn?	Luke Timmerman	05/16/11	National
Varian Invests $15M in Augmenix	Luke Timmerman	05/12/11	Boston
SpringLeaf Snags $15M for New Self-Injection System for Biotech Drugs	Luke Timmerman	05/12/11	Boston
Pageonce Adds $15M	Wade Roush	05/11/11	San Francisco
CardioDx Raises $60M	Luke Timmerman	05/11/11	San Francisco
Raising Capital At-The-Market: a Prescription for a Solid Long-Term Financing Strategy	Todd Wyche	05/11/11	New York
The Challenge of Financing Renewable Fuels: A Chat With James Dack of Stern Brothers	Luke Timmerman	05/06/11	Seattle
SeaGen Ends March With $456M Cash	Luke Timmerman	05/05/11	Seattle
Geron Nabs $25M Loan from Stem Cell Agency, Paves Way for State Support of Clinical Trials	Luke Timmerman	05/05/11	San Francisco
Dendreon Gets $28M Revenue in Q1	Luke Timmerman	05/02/11	Seattle
Assessing the Best M&A Opportunities for 2011	Taft Kortus	05/02/11	Seattle
Oncothyreon Tacks On $40M	Luke Timmerman	04/29/11	Seattle
Gates Foundation Dishes Out Latest $100K Grants for ‘Out of the Box’ Global Health Ideas	Luke Timmerman	04/28/11	Seattle
Acucela Adds Finance Chief	Luke Timmerman	04/26/11	Seattle
Sean Tunis, Former Medicare Guru, on What Biotechies Gotta Do the Next Five Years	Luke Timmerman	04/26/11	Seattle
Cytokinetics Adds $20M	Luke Timmerman	04/18/11	San Francisco
Kineta Gets $1M NIH Contract Extension	Luke Timmerman	04/11/11	Seattle
Optivia Gets $1.8M For Drug Interaction Study	Luke Timmerman	04/05/11	San Francisco
AVI Biopharma Adds $30M	Luke Timmerman	04/01/11	Seattle
Arena Adds $35.5M	Luke Timmerman	03/29/11	San Diego
Canaan Strings Together Some Good News, Just as the Pressure Mounts on VC Model	Luke Timmerman	03/24/11	San Francisco
Who’s Going to Pay for Future Drug Development? (Part 2)	Stewart Lyman	03/23/11	National
Who’s Going to Pay for Future Drug Development? (Part 1)	Stewart Lyman	03/22/11	National
Think Obamacare Will Suffocate New Drug Development With Price Controls? Think Again	Luke Timmerman	03/21/11	National
Affymax Raises $50M	Luke Timmerman	03/18/11	San Francisco
Exelixis Tacks on $23M	Luke Timmerman	03/15/11	San Francisco
Solazyme Seeks $100M IPO to Build Up Renewable Biofuel Business	Luke Timmerman	03/14/11	San Francisco
Exelixis Bags $156M, Tethys Bets on Prevention, UCSF’s Delicate Dance With Industry, & More Bay Area Life Sciences News	Luke Timmerman	03/11/11	San Francisco
Exelixis Pockets $156M in Stock Sale, Riding Wave of Prostate Cancer Drug Results	Luke Timmerman	03/09/11	San Francisco
Burrill’s Bet on Seattle, Yamada Exits Gates Foundation, Stewart Parker’s New Gig, & More Seattle-Area Life Sciences News	Luke Timmerman	02/17/11	Seattle
Page 2 of 11	« previous page · next page »

Entry

Author

Date

Location

Will Biotech Ever Again Captivate the Public Imagination, Like Facebook or LinkedIn?

Luke Timmerman

05/16/11

National

Varian Invests $15M in Augmenix

Luke Timmerman

05/12/11

Boston